Posted by Michael Wonder on 11 Apr 2022
Spectrum Pharmaceuticals announces FDA acceptance of BLA resubmission for eflapegrastim
11 April 2022 - FDA has assigned 9 September 2022 as the PDUFA date.
Spectrum Pharmaceuticals today announced that the resubmitted biologics license application for eflapegrastim has been accepted for filing.
